ProQR Therapeutics PRQR 深 沪
已收盘 08-15 16:00:00 美东时间
2.05
+0.030
+1.49%
华盛通- 最 高2.06
- 今 开2.02
- 成交量 12.48万股
- 最 低 2.00
- 昨 收 2.02
- 总市值 2.15亿
- 52周最高 4.62
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 1.07
- 委 比 -87.28%
- 总股本 1.05亿
- 历史最高 27.60
- 量 比 0.34
- 振 幅 2.97%
- 历史最低 0.53
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
08-08 20:16
ProQR GAAP EPS of -€0.12, revenue of €3.82M
ProQR press release (NASDAQ:PRQR): Q2 GAAP EPS of -€0.12. Revenue of €3.82M (-39.5% Y/Y). More on ProQR Seeking Alpha’s Quant Rating on ProQR Historical earnings data for ProQR Financial information f...
08-07 20:00
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share
08-07 19:25
ProQR Announces Upcoming Presentation at RNA Editing Summit
ProQR Therapeutics will participate in the RNA Editing Summit in Boston, July 29-31, 2025. Gerard Platenburg, Chief Scientific Officer, will present preclinical data on Axiomer RNA editing technology's potential in treating severe neurodevelopmental diseases, such as Rett syndrome targeting MECP2. The presentation will also highlight Axiomer's applications in the CNS and liver, showcasing its versatility in addressing diverse diseases.
07-28 12:00
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
06-27 20:31
ProQR Submits CTA for Phase 1 Study of AX-0810
ProQR ( ($PRQR) ) just unveiled an update. On June 26, 2025, ProQR Therapeutics...
06-27 05:01
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Therapeutics has submitted a Clinical Trial Application to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of AX-0810, a novel RNA editing oligonucleotide targeting NTCP, a liver cell protein. AX-0810 aims to reduce toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure in cholestatic diseases. The Phase 1 study will evaluate safety, tolerabilit...
06-26 20:30
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
